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Current influenza virus vaccines are based on strain-specif-
ic surface glycoprotein hemagglutinin (HA) antigens and 
effective only when the predicted vaccine strains and circu-
lating viruses are well-matched. The current strategy of in-
fluenza vaccination does not prevent the pandemic out-
breaks and protection efficacy is reduced or ineffective if 
mutant strains emerge. It is of high priority to develop effec-
tive vaccines and vaccination strategies conferring a broad 
range of cross protection. The extracellular domain of M2 
(M2e) is highly conserved among human influenza A vi-
ruses and has been utilized to develop new vaccines induc-
ing cross protection against different subtypes of influenza 
A virus. However, immune mechanisms of cross protection 
by M2e-based vaccines still remain to be fully elucidated. 
Here, we review immune correlates and mechanisms con-
ferring cross protection by M2e-based vaccines. Molecular 
and cellular immune components that are known to be in-
volved in M2 immune-mediated protection include anti-
bodies, B cells, T cells, alveolar macrophages, Fc receptors, 
complements, and natural killer cells. Better understanding 
of protective mechanisms by immune responses induced by 
M2e vaccination will help facilitate development of broad-
ly cross protective vaccines against influenza A virus.
[Immune Network 2015;15(5):213-221]
Keywords: Influenza virus, M2e, Universal vaccine, Im-
mune mechanism
INTRODUCTION
Influenza viruses are enveloped, single-stranded, neg-
ative-sense RNA viruses and belong to the family Ortho-
myxoviridae. Influenza viruses are classified into main 
types A, B, and C. These main antigenic types are differ-
entiated not only on the basis of antigenic differences in 
their nucleocapsid (NP) and matrix (M) proteins, but also 
with respect to the number of gene segments and viral pro-
teins, host range and capacity to cause disease (1). Influen-
za B viruses are restricted to human hosts. Influenza A vi-
ruses that have many different hosts including humans, 
birds, and pigs are divided into subtypes based on hemag-
glutinin (HA) and neuraminidase (NA) proteins on the sur-
face of the virus. At present, 18 different HA (H1-H18) 
and 11 different NA (N1-N11) molecules are known to ex-
ist (2). 
  The gene 7 among 8 segmented genes of influenza A 
virus is bicistronic, encodes both M1 and M2 proteins. The 
M2 protein is derived from the co-linear (M1) transcript 
by splicing. M2 is an integral membrane protein, whose 
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membrane-spanning domain also serves as a signal for 
transport to the cell surface. M2 protein is also known to 
be a proton-selective ion channel to control the pH of the 
Golgi during HA synthesis and responsible for the acid-
ification of the viral interior during uncoating and mem-
brane fusion (3,4). The 23-amino acid sequence in the ex-
tracellular domain of M2 (M2e) is well conserved among 
human influenza A viruses although there are few residue 
changes among non-human host species such as avian and 
swine influenza A viruses (5-7). Especially, the MSLL-
TEVET sequence (aa 1-9) in M2e was found to be con-
served at a rate of over 99% among all influenza A viruses 
(5,8) because these residues are shared with those of M1. 
Therefore, M2e-based vaccines may be developed into at-
tractive candidates for a universal influenza vaccine with 
a broad spectrum of prevention.
  M2e itself is known as a very poor immunogen. Even 
live influenza virus infection generating strong humoral 
and cellular immunity is not effective in inducing M2e- 
specific antibodies in a mouse model (9,10). Therefore, 
previous studies have focused on increasing the immuno-
genicity of M2e using a variety of carrier vehicles or in 
combination with various adjuvants. Examples of carrier 
vehicles for M2e antigens include hepatitis B virus core 
particles (11-13), human papillomavirus L proteins (14), 
phage Qβ-derived protein cores (15), keyhole limpet he-
mocyanin (16), bacterial outer membrane complexes (12, 
17), liposomes (18), cholera toxin subunit (19), flagellin 
(20), and virus-like particles (9). Adjuvant formulations 
that were reported with M2e antigens include complete or 
incomplete Freund’s adjuvant (12,16,21), monophosphoryl 
lipid A (MPL) (18,19,22,23), cholera toxin subunits (24), 
heat-labile endotoxin (8,11,13,25), cholera toxin, and lip-
osome based cationic adjuvant (26). Also, recombinant live 
vectors expressing M2e antigens that were tested in animal 
models are to utilize adenovirus (16) or modified vaccinia 
virus Ankara (27). Most studies described above reported 
that M2e-based vaccines even with potent experimental ad-
juvants can provide survival protection but are not capable 
of completely preventing weight loss after lethal challenge 
with different strains of influenza A virus. Thus, studies 
on the protective efficacies by M2e-based vaccination, in-
volving a certain degree of body weight loss, suggest that 
M2e immunity-mediated cross protection is relatively weak. 
Despite extensive reports with M2e-based vaccines, the 
mechanism studies of cross protection by the immune re-
sponses induced by M2e vaccination have been relatively 
rare. Most licensed human vaccines are based on the in-
duction of neutralizing antibodies. However, M2e im-
munity confers protection through non-neutralizing im-
mune mechanisms. In this article, we have reviewed the 
possible immune mechanisms of M2e-mediated protection.
M2e ANTIBODIES AND ANTIGENIC BINDING 
PROPERTIES
The M2 protein is not only expressed at a low level on 
the virions but also shielded by the larger and more abun-
dant surface HA and NA glycoproteins (28). Immunization 
with whole-inactivated or split influenza vaccine in mice 
was not effective in inducing M2e-specific antibodies (10, 
22,28-30), probably because shielding effects by HA and 
NA proteins might prevent the access of M2e to immune 
effector cells. In contrast, the M2 protein is expressed at 
high levels on the plasma membrane surfaces of virus-in-
fected cells (31,32). Mouse anti-M2e monoclonal antibody 
14C2 has been reported to reduce plaque sizes of some 
influenza A virus strains in vitro but not other strains 
(A/PR/8/34, A/WSN/34) (32). Moreover, passive immuno-
therapy with 14C2 monoclonal antibody reduced human 
influenza virus replication in the lung of mice (33). 
  M2e vaccines either in carrier vehicles or in adjuvant 
formulations were shown to induce M2e-specific anti-
bodies conferring survival advantages but not being able 
to prevent weight loss upon lethal infection. M2e vac-
cine-induced M2e antibodies are highly effective in bind-
ing to M2e peptide antigens but show low or no reactivity 
to M2 protein antigens on influenza virions (9,34,35). M2e 
vaccine immune sera were shown to be reactive to M2 
proteins expressed on the surfaces of infected cells (34- 
35). In general, M2 immunity provides weak protective ef-
ficacy, which might be due to the fact that anti-M2e anti-
bodies cannot neutralize the virus in vitro (33,35,36). 
IMPROVED CROSS PROTECTION BY 
HETEROLOGOUS M2e DOMAINS PRESENTED 
ON VIRUS-LIKE PARTICLES
Although M2e sequences are highly conserved in human 
influenza A viruses, there are minor variations in the M2e 
sequences derived from avian and swine influenza A vi-
ruses (5). In a strategy to overcome these M2e sequence 
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Table I. Humoral and cellular immune mechanisms for M2e immunity
mAb, Vaccines Humoral mechanism Cellular mechanism References
M2e mAb (14C2) Plaque reduction (32)
M2e mAb (14C2) Passive protection (33)
M2e-HBc IgG1, IgG2a NK cells-mediated ADCC (35)
M2 DNA/Adenovirus IgG CD4＋ and CD8＋ T cells (depletion) (16)
CTA1-M2e-DD IgG1, IgG2a B cell-independent, MHCII-CD4＋ T cells (19)
M2 VLP /inactivated virus IgG, protection against body weight loss Macrophages, dendritic cells (29)
M2e5x VLP/AS04 IgG Granzyme B＋, IFN-γ＋CD4＋ T cells (22)
M2e-HBc immune IgG Passive immunization and protection FcγRI, FcγRIII-dependent alveolar 
macrophages (Passive)
(47)
M2e5x VLP IgG, protection CD4＋, CD8＋ T cells, Fc receptors (active) (48)
M2e5x VLP IgG1, IgG2a, virus binding, protection Fc receptors (passive) (10)
M2e5x VLP IgG1, IgG2a, virus binding, long-term 
protection (8 months)
IFN-γ＋ spleen cells (9)
M2e5x VLP/split vaccine IgG1, IgG2a, protection against body 
weight loss
Fc receptors (passive), CD4＋, CD8＋ 
T cells (depletion)
(30)
M2e mAb (Z3G1) mAb IP passive immunization and protection C3-dependent reduction in viral loads (56)
M2e-HBc sera Polyclonal IgG, IP passive protection C3-independent protection (35)
M2e mAb, M2e specific monoclonal antibody; M2e-HBc, M2e-hepatitis B virus core fusion protein; M2 VLP, virus-like particles (VLP) 
presenting the wild type M2 protein; M2e5x VLP, VLP presenting a heterologous tandem repeat of M2e epitope sequences (M2e5x) of 
human, swine, and avian origin influenza A viruses; NK cells, natural killer cells; ADCC, antibody-dependent cellular cytotoxicity; 
CTA1-M2e-DD, M2e fusion protein vaccine to cholera toxin subunit A1 and a dimer of the D-fragment of Staphylococcus aureus protein 
A; AS04, adjuvant of alum plus monophosphoryl lipid A (MPL), Protection against body weight loss indicates significantly improved 
cross protection by preventing severe weight loss. 
variations, a heterologous tandem repeat of M2e epitope 
sequences (M2e5x) of human, swine, and avian origin in-
fluenza A viruses was expressed in a membrane-anchored 
form and incorporated into virus-like particles (M2e5x 
VLP) (9,10). The M2e epitope density of M2e5x construct 
on VLPs as probed by M2e specific monoclonal antibody 
was detected at hundreds fold higher than those in influen-
za virions and wild type M2 on VLPs (9,10). Recombinant 
M2e5x VLP vaccine has several unique features using ge-
netic engineering techniques, which are different from oth-
er M2e vaccines. (i) The M2e5x protein contains heterolo-
gous M2e sequences with a linear tandem array of con-
served M2e sequences derived from human, swine, and 
avian host origin influenza A viruses for broader cove-
rages. (ii) The oligomerization domain of general control 
nondepressible 4 (GCN4) to stabilize oligomer formation 
was genetically fused to the C-terminal part of M2e5x. (iii) 
The signal peptide from the honeybee protein melittin was 
added to the N-terminus of M2e5x, which is known for 
efficient expression on insect cell surfaces (37). (iv) 
Finally, the transmembrane and cytoplasmic tail domains 
were replaced with those derived from HA to take advant-
age of its high levels on influenza virus, expecting for effi-
cient incorporation into VLPs.
  Immunization of BALB/c mice with M2e5x VLP ex-
perimental vaccines effectively induced M2e antibodies that 
were highly reactive to M2e antigens of human, swine, and 
avian influenza viruses. Serum antibodies induced by 
M2e5x VLP immunization were found to be highly reactive 
with different influenza viruses including H1N1, H3N2 and 
H5N1 subtypes (9,10). Compared to mono M2e or homolo-
gous tandem M2e vaccines, M2e5x VLP vaccine was dem-
onstrated to be highly efficacious in conferring cross pro-
tection against H1N1, H3N2, and H5N1 subtype viruses 
by 100% protection with preventing severe weight loss in 
the absence of exogenous adjuvants (9,10). In addition, im-
mune sera were found to be sufficient for conferring cross 
protection against H1N1, H3N2, and H5N1 influenza virues 
in naïve mice (9,10). It is significant to provide strong evi-
dence that M2e-specific antibodies can have cross pro-
tective roles although these M2e antibodies lack in vitro 
virus neutralizing activity. However, it is difficult to com-
pare the efficacy of different M2e-based vaccines that were 
reported by other laboratories under different conditions.
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MECHANISMS OF M2e-BASED VACCINES IN 
CONFERRING CROSS PROTECTION AGAINST 
INFLUENZA
Multiple mechanisms might be involved in conferring pro-
tection by M2e-specific antibodies. It was suggested that 
M2e-specific antibodies could perturb crucial interactions 
between the M1 and M2 proteins and subsequently inter-
fere with the interaction of the M1 protein with the HA 
protein, the NA protein, and the nucleocapsid complexes, 
thus interfering with virus assembly and causing growth 
restriction (7). Moreover, anti-M2e antibodies bind strong-
ly to the virus-infected cells, proposing indirect mecha-
nisms of protection. Non-neutralizing antibody-mediated 
protective mechanisms are antibody-dependent cellular cy-
totoxicity (ADCC), complement-dependent cytolysis (CDC), 
preventing the release of viral particles into the extra-
cellular fluids, and/or enhancing the uptake by phagocytic 
cells. Potential immune mechanisms by which M2e-based 
vaccines or M2e antibodies confer protection are summar-
ized in the Table 1.
Roles of Fc receptors in conferring cross protection by 
M2e antibodies
Neutralization of virions is believed to be the primary 
function of antibodies in anti-viral immunity (38-43). It is 
also known that Fc receptor (FcR)-mediated phagocytosis 
by macrophages plays a pivotal role in clearance of influ-
enza A virus-infected cells (44,45). Previous studies have 
shown that anti-M2e antibodies passively transferred could 
mediate protection against influenza infection in vivo 
(13,46). Given the fact that anti-M2e antibodies are non- 
neutralizing antibodies, FcR-mediated opsonophagocytosis 
by macrophages could be essential for M2e-specific anti-
body-mediated immune protection. El Bakkouri et al. dem-
onstrated that alveolar macrophages and FcR-dependent 
elimination of influenza A virus-infected cells are crucial 
for protection by anti-M2e IgG using passive immuniza-
tion experiments in wild-type and FcR common γ chain 
deficient (FcR γ−/−) mice models as well as a conditional 
cell depletion and adoptive transfer protocol (47). More-
over, Song et al. also reported that cross protection against 
influenza A virus by M2e-immune sera is mediated by 
dendritic cells and macrophages as shown by depletion ex-
periments using clodronate-liposomes (20).
  To better understand M2e immune-mediated protection, 
antibody levels and protective efficacy were compared be-
tween FcR γ−/− and wild type BALB/c mice that were 
immunized with M2e5x VLP (48). M2e antibodies in FcR 
γ−/− mice were induced at similar levels and showed 
equal protective capacity as observed in wild type BALB/c 
mice. However, M2e5x VLP-immunized FcR γ−/− mice 
were much less protected than M2e5x VLP-immunized 
wild type mice after lethal challenge. In contrast, FcR γ−/− 
mice that were immunized with inactivated influenza virus 
effectively induced hemagglutination inhibition (virus neu-
tralizing) activity and were well protected. These studies 
indicate that HA-based vaccines inducing virus neutraliz-
ing antibodies confer strain-specific protection in an Fc re-
ceptor independent mechanism whereas M2e antibody- 
mediated cross protection requires Fc receptors (48). In 
line with this mechanism, immune sera with M2e anti-
bodies showed much less protective efficacies in FcR γ−/− 
mice compared to those in wild type mice using a modi-
fied passive immunization approach (10,30). Taken togeth-
er, a possible explanation is that M2e-specific antibodies 
are contributing to protection via FcR expressing host im-
mune cell-dependent mechanisms because these antibodies 
cannot directly neutralize influenza A virus. Alternatively, 
anti-M2e antibodies may promote the adaptive response by 
enhancing uptake of antibody-bound virions via dendritic 
cells and macrophages which are not by themselves suffi-
cient for protection. It is also possible that immune-com-
plex activated dendritic cells and macrophages further con-
tribute to increasing antiviral IFN-γ-secreting T cell res-
ponses.
Roles of natural killer cells in conferring cross 
protection by M2 immune responses
The FcR γ subunit is known to be required for antibody- 
mediated phagocytosis by macrophages and for natural 
killer (NK) cell-dependent ADCC (35). In mice, contra-
dictory findings have been reported with regards to the in-
volvement of ADCC by NK and/or NK T cells in M2e- 
mediated protection (35,49). Jegerlehner et al. proposed an 
important role for ADCC by NK cells in acquiring anti- 
M2e immunity (35). Meanwhile, other studies (49,50) ar-
gued for a different immune mechanism by M2e-mediated 
protection rather than NK cell-mediated ADCC. Consider-
ing several differences in experimental protocols, it is dif-
ficult to reconcile contradictory findings on the role of NK 
cells in the M2e-mediated protection in mice. Recently, it 
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has been reported that human NK cell-mediated ADCC 
against M2-expressing cells as well as pro-inflammatory 
cytokine and chemokine secretion from NK cells were en-
hanced in the presence of human anti-M2e monoclonal an-
tibody Ab1-10 (51). Thus, it is likely that NK cells may 
contribute to M2e immune mediated protection via multi-
ple mechanisms.
Roles of complement protein C3 in conferring cross 
protection by M2e vaccines
Complement can also play an essential role in virus elimi-
nation (52-54). Beebe et al. reported that complement can 
bind to influenza virus in the presence of virus-specific an-
tibodies (55). Moreover, the classical complement pathway 
can be activated by antigen-antibody immune complexes, 
ultimately leading to CDC. However, the role of comple-
ment in M2e-mediated immune response is also controver-
sial. Jegerlehner et al. demonstrated that the complement 
component C3 is not critical for anti-M2e antibody-media-
ted protection by intraperitoneal passive transfer of M2e- 
immune sera (35). In contrast, Wang et al. suggested that 
complement is required for reducing lung viral loads in in-
fected mice using passive immunization of human an-
ti-M2e monoclonal antibodies in C3−/− mice model (56). 
This discrepancy might be due to the differences in experi-
mental protocols. The IgG2a isotype antibody is known to 
be involved in binding to FcRs more effectively than IgG1 
isotype (44,57-59). Mice were immunized by M2-hepatitis 
B core (M2-HBc) particles used in Jegerlehner’s experi-
ments showed that endpoint titers of M2e-specific IgG1 
isotype antibody were approximately 10-fold higher than 
that of M2e-specific IgG2a isotype antibody (23). It is pos-
sible that a profile of specific IgG isotypes might play a 
role in differential effects on the dependency of FcRs or 
complement. Further studies are needed to better under-
stand the possible roles of complement C3 in conferring 
protection by using an appropriate vaccine that can elicit 
a T helper type 1-biased antibody immune response.
Roles of M2e-specific T cell responses in conferring 
M2e immunity by vaccination
Optimum protection against influenza A virus requires anti-
body production by B cells as well as cytotoxic cellular 
and soluble cytokine mechanisms mediated by T cells (60). 
Activated influenza-specific T cells have been shown to 
be associated with protection against influenza in human 
studies (61,62). Several studies have shown that M2e-spe-
cific T cells can mediate protection against influenza in-
fection in vivo (16,19,30,48). Eliasson et al. have demon-
strated that an M2e-specific CD4＋ T cell but not CD8＋ 
T cell response was induced in BALB/c mice that were 
intranasally immunized with protein fusion vaccine 
(CTA1-M2e-DD of cholera toxin subunit A1 and a dimer 
of the D-fragment of Staphylococcus aureus protein A) in 
the presence of immune stimulatory complex ISCOMS ad-
juvant (19). Anti-influenza CD8＋ cytotoxic T lymphocyte 
activity is also known to contribute to recovery from influ-
enza infection in mice (63). Other studies have demon-
strated the presence of MHC class I or II restricted epitopes 
in M2e in mice or human (64-66). Although it is not clear 
why there is discrepancy in T cell responses among differ-
ent studies, differences in immunization protocols such as 
the platforms of vaccines and adjuvants, strains of animals, 
routes of immunization and with or without adjuvants may 
affect the differential outcomes of immune responses. 
  Specific T cell depletion approaches in vaccinated mice 
are often used to determine the roles of T cells in confer-
ring protection. In a previous study of M2-DNA and ad-
enoviral vector vaccines (16), BALB/c mice that were im-
munized with M2-DNA prime and M2-recombinant ad-
enovirus boost were treated with CD4, CD8, or CD4 plus 
CD8 antibodies prior to viral challenge. M2-DNA/ad-
enovirus immune mice with depletion of both CD4＋ and 
CD8＋ T cell but not either single CD4＋ or CD8＋ T cell 
showed significant lower efficacy of survival protection in-
dicating the roles of CD4＋ and CD8＋ T cells in conferring 
M2 immunity (16). Using a similar approach, Kim et al. 
have reported differential effects on the roles of CD4＋ and 
CD8＋ T cells in mice that were immunized with split vac-
cine plus M2e5x VLP (30). Split-M2e5x VLP immune 
mice with depletion of CD4＋ T cells showed significant 
more weight loss than the CD8＋ T cell depleted mice, in-
dicating that CD4＋ T cells appeared to play a greater role 
than CD8＋ T cells in conferring cross protection (30). Of 
course, severe weight loss was observed in Split-M2e5x 
VLP immune mice with depletion of both CD4＋ T and 
CD8＋ T cells, providing further evidence that both CD4＋ 
T and CD8＋ T cells play an important role conferring 
cross protection via M2e-based vaccines. In line with these 
above studies, M2e5x VLP immune FcR γ−/− mice in-
duced higher frequency of M2e-specific IFN-γ-producing 
CD4＋ and CD8＋ T cells as well as lower lung viral titers 
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compared to those of naïve FcR γ−/− mice post challenge 
(48). Therefore, it is likely that M2e-specific CD4＋ and 
CD8＋ T cell immunity plays an important role during re-
covery from illness caused by influenza virus infection if 
immunogenic M2e vaccines are used to induce T cell 
immunity.
SUPPLEMENTED VACCINATIONS WITH A 
REALISTIC GOAL OF CONFERRING 
BROADER CROSS PROTECTION
Developing a truly cross protective single shot universal 
vaccine might not be a realistic goal due to the extremely 
high genetic and antigenic differences among influenza vi-
ruses as well as the relatively low immunogenicity and ef-
ficacy of conserved antigenic targets. To overcome the low 
immunogenicity and efficacy of M2e, most animal studies 
were carried out using M2e-conjugate vaccines in a range 
of high doses (40 to 100 µg per mouse) and multiple im-
munizations in the presence of potent adjuvants inap-
propriate for human use. 
  A more realistic approach for inducing broader cross 
protection would be to supplement current platforms of 
strain-sepcific HA-based influenza vaccines with a highly 
conserved antigenic target vaccines such as M2e. Song et 
al. (2011) demonstrated that an inactivated influenza vac-
cine supplemented with M2 VLPs can significantly im-
prove cross protective efficacy by preventing weight loss 
and conferring protection against H1N1, H3N2, and H5N1 
influenza viruses (29). In a recent study to further support 
the concept of supplemented vaccination, co-immunization 
with licensed split vaccine plus M2e5x VLP significantly 
improved the efficacy of cross protection compared to that 
of split vaccine alone (30). Also, immune sera from sup-
plemented vaccination were shown to confer improved 
cross protection in naïve mice (30). In real world, most 
humans have a certain level of pre-existing immunity to 
influenza either by vaccination or natural infection. To 
mimic this heterogeneity with pre-existing immunity, mice 
that were previously immunized with split vaccine were 
subsequently immunized with M2e5x VLPs and evaluated 
to assess the cross protective efficacy against hetero-
subtypic viruses (22). Subsequent supplemental immuniza-
tion with M2e5x VLPs significantly enhanced the cross 
protective efficacy of pre-existing HA immunity (22). To 
further move forward this concept of supplementation with 
a conserved M2e epitope vaccine to clinical trials, the effi-
cacy of M2e5x VLP supplementation should be tested in 
a more relevant ferret animal model. 
CONCLUSION
Influenza viruses are continuously evolving, introducing 
various mutations to the surface glycoproteins HA and 
NA, or transferring new HA and/or NA genes from other 
species stains to human influenza viruses. Current vacci-
nation is based on immunity to HA, mainly aiming to in-
duce vaccine strain-specific neutralizing antibodies. When 
the prediction of a circulating strain in the next season is 
well matched with a chosen vaccine strain, the efficacy is 
sufficiently high. However, current strategy has a major 
drawback of being unable to protect against a new strain 
with an antigenically different HA. 
  The concept behind developing universal vaccines is to 
utilize the highly conserved antigenic target such as M2e 
and to make it immunogenic sufficient enough for induc-
ing protective immunity. However, the protective immune 
mechanisms of the immune responses induced by M2e 
vaccination remain to be fully elucidated and further stud-
ies are needed for a better understanding. It will provide 
highly informative insight into developing novel new vac-
cines if we better understand the immunological mecha-
nisms of how universal vaccines work and what immune 
components involve in the protection against different 
strains of influenza A virus. Based on mechanistic under-
standing, it is expected that effective and safe M2e-specific 
influenza vaccines will be developed for prevention of sea-
sonal and pandemic influenza in near future. 
  A caveat is that most human vaccines were licensed by 
proven criteria of inducing neutralizing antibodies. As re-
viewed above, protective immune mechanisms by which 
M2e immunity works rely on the induction of cross pro-
tective non-neutralizing antibodies and T cell responses. 
Due to the nature of M2 immune-mediated protection, de-
veloping standalone broadly cross protective universal in-
fluenza vaccines to completely replace the current annually 
updating influenza vaccination program would be an ideal 
goal. Instead, an achievable approach will be to develop 
simple vaccination of supplementing strain-specific current 
influenza vaccines with a highly conserved M2e antigenic 
target in an effective platform such as VLPs. 
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